Dave Murphy's experience as an analytical chemist encompasses the key activities associated with the chemistry, manufacturing and control (CMC) of new medicinal products.
Savanta can provide expertise in the analysis of both drug substance and formulated products, including pre-formulation and formulation development activities, method development and validation, stability testing and support in the compilation of regulatory documents.
This knowledge can be applied at the earliest stage of development in the pre-clinical phase through to phase I, phase II and phase III of the clinical development process.
Pharmaceutical analysis consultancy services are offered to support both the synthesis and characterisation of drug substances (or Active Pharmaceutical Ingredient, API) and also for the development of formulated products (or Investigational Medicinal Product, IMP).
Although these represent two major parts of the development process, Savanta endeavors, where possible, to integrate activities to maximize the efficiency and output of the analytical process.